Accéder au contenu
Merck

CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1α-induced twist expression.

Oncotarget (2017-11-02)
Po-Chun Chen, Huai-Ching Tai, Tien-Huang Lin, Shih-Wei Wang, Chih-Yang Lin, Chia-Chia Chao, Hong-Jeng Yu, Yu-Chieh Tsai, Yu-Wei Lai, Chiao-Wen Lin, Chih-Hsin Tang
RÉSUMÉ

Epithelial-mesenchymal transition (EMT) has received considerable attention as a conceptual paradigm for explaining metastatic behavior during cancer progression. NOV/CCN3 is a matrix-associated protein involved in many cellular functions. Previous studies have shown that CCN3 expression is upregulated in prostate cancer (PCa) cells and in PCa patients. In this study, we have provided evidence of tumor promoting effects of CCN3, which includes induction of epithelial-to-mesenchymal transition (EMT) and tumor metastasis. We used an orthotopic

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting human NOV